MEGAN SEIFERT: Open Payments
NPI 1609363852 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$566 in 37 payments from 11 companies in 2025. Trend: 2023 $656 · 2024 $1,253 · 2025 $566
Food & beverage: $566
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $181 |
| Axsome Therapeutics, Inc. | 8 | $88 |
| Vanda Pharmaceuticals Inc. | 4 | $88 |
| Indivior Inc. | 2 | $44 |
| Tris Pharma Inc | 2 | $34 |
| Alkermes, Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $18 |
| PFIZER INC. | 1 | $16 |
Products named: VRAYLAR, HETLIOZ, Auvelity, MAVYRET, SUBLOCADE, Dyanavel XR, ARISTADA, CAPLYTA.
Industry payments across IN — which companies pay providers there.
